

## DESCRIPTION

<b>Species Reactivity</b>	Equine
<b>Specificity</b>	Detects equine IL-1ra/IL-1F3 in ELISAs and Western blots. In sandwich immunoassays, less than 20% cross-reactivity with recombinant mouse IL-1ra is observed, less than 5% cross-reactivity with recombinant rat IL-1ra is observed, less than 2% cross-reactivity with recombinant porcine IL-1ra is observed, less than 0.4% cross-reactivity with recombinant human IL-1ra is observed, and less than 0.2% cross-reactivity with recombinant equine IL-1beta is observed.
<b>Source</b>	Polyclonal Goat IgG
<b>Purification</b>	Antigen Affinity-purified
<b>Immunogen</b>	<i>E. coli</i> -derived recombinant equine IL-1ra/IL-1F3 His26-Gln177 Accession # O18999
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.


## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Western Blot</b>	0.1 µg/mL	Recombinant Equine IL-1ra/IL-1F3 (Catalog # <a href="#">2466-RA</a> )
<b>Immunocytochemistry</b>	5-15 µg/mL	See Below
<b>Equine IL-1ra/IL-1F3 Sandwich Immunoassay</b>		<b>Reagent</b>
<b>ELISA Capture</b>	0.2-0.8 µg/mL	Equine IL-1ra/IL-1F3 Antibody (Catalog # <a href="#">AF2466</a> )
<b>ELISA Detection</b>	0.1-0.4 µg/mL	Equine IL-1ra/IL-1F3 Biotinylated Antibody (Catalog # <a href="#">BAF2466</a> )
<b>Standard</b>		Recombinant Equine IL-1ra/IL-1F3 (Catalog # <a href="#">2466-RA</a> )

## DATA

### Immunocytochemistry



#### IL-1ra/IL-1F3 in Equine PBMCs.

IL-1ra/IL-1F3 was detected in immersion fixed equine peripheral blood mononuclear cells (PBMCs) using Goat Anti-Equine IL-1ra/IL-1F3 Antigen Affinity-purified Polyclonal Antibody (Catalog # [AF2466](#)) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # [NL001](#)) and counterstained with DAPI (blue). Specific staining was localized to plasma membrane. View our protocol for [Fluorescent ICC Staining of Non-adherent Cells](#).

## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.2 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

Secreted equine IL-1 receptor antagonist (IL-1ra) is a presumably 22-25 kDa glycoprotein produced by variety of cell types that antagonizes IL-1 activity (1-3). It is a member of the IL-1 family of proteins that includes IL-1 $\alpha$  and IL-1 $\beta$ . Although there is little amino acid (aa) identity (<30%) among the three IL-1 family members, all molecules bind to the same receptors, all show a  $\beta$ -trefoil structure, and all are believed to have evolved from a common ancestral gene (1-4). Equine IL-1ra is synthesized as a 177 aa precursor that contains a 25 aa signal sequence plus a 152 aa mature region. There is one intrachain disulfide bond and one potential N-linked glycosylation site (3, 5, 6). Mature equine sIL-1ra is 78%, 78%, 80%, 82%, and 76% aa identical to mature mouse, human, porcine, canine and bovine IL-1ra, respectively. In human, three non-secreted IL-1ra isoforms have also been identified. It is unknown if such an analogous situation exists in equine. Cells known to secrete IL-1ra include fibroblasts, vascular smooth muscle cells, intestinal columnar epithelium, chondrocytes, macrophages, mast cells, neutrophils and hepatocytes.

There are two type I transmembrane glycoprotein receptors for IL-1ra. The first is the bioactive 80 kDa type I IL-1 receptor (IL-1 RI), and the second is the inert (decoy) 65 kDa type II IL-1 receptor. IL-1ra binding to IL-1 RI competitively blocks IL-1 ( $\alpha$  or  $\beta$ ) binding to the same receptor. This results in receptor ligation without activation (1, 7). The type II IL-1 receptor is inert, and any binding of IL-1ra not only fails to block co-existing IL-1 activity, but may actually potentiate it by removing an IL-1 antagonist. Functionally, all activities attributed to IL-1ra are explained by its role as a competitive inhibitor of IL-1 binding to IL-1 RI (1, 2, 8, 9).

## References:

1. Arend, W.P. *et al.* (1998) Annu. Rev. Immunol. **16**:27.
2. Roux-Lombard, P. (1998) Eur. Cytokine Netw. **9**:565.
3. Dayer-J-M. (2002) Clin. Exp. Rheumatol. **20**(27):S14.
4. Eisenberg, S.P. *et al.* (1991) Proc. Natl. Acad. Sci. USA **88**:5232.
5. Kato, H. *et al.* (1997) Vet. Immunol. Immunopathol. **56**:221.
6. Howard, R.D. *et al.* (1998) Am. J. Vet. Res. **59**:712.
7. Dinarello, C.A. (1997) Semin. Oncol. (Suppl 9):S9.
8. Irikura, V.M. *et al.* (2002) J. Immunol. **169**:393.
9. Arend, W.P. and C. Gabay (2000) Arth. Res. **2**:245.